An Act to amend the Patent Act

This bill was last introduced in the 37th Parliament, 1st Session, which ended in September 2002.


Judy Wasylycia-Leis  NDP

Introduced as a private member’s bill. (These don’t often become law.)


Not active, as of May 2, 2002
(This bill did not become law.)


All sorts of information on this bill is available at LEGISinfo, provided by the Library of Parliament. You can also read the full text of the bill.

Patent ActRoutine Proceedings

May 2nd, 2002 / 10:10 a.m.
See context


Judy Wasylycia-Leis NDP Winnipeg North Centre, MB

moved for leave to introduce Bill C-460, an act to amend the Patent Act.

Madam Speaker, it gives me great pleasure today to introduce the bill, an act to amend the Patent Act to remove the Patented Medicines (Notice of Compliance) Regulations.

This measure would significantly reduce the costs of drugs to Canadians and has to be part of any comprehensive pharmacare strategy to reel in skyrocketing drug costs.

The bill would eliminate a piece of patent legislation whose only function is to artificially prolong high profits for brand name drug companies.

By activating this process, these corporations receive automatically a 24 month injunction preventing generic drug manufacturers from producing cheaper versions of drugs whose patents would otherwise have expired.

It is time to end this unjustifiable perk given to brand name drug companies and to take this small step toward ensuring access for all Canadians to necessary prescription drugs.

(Motions deemed adopted, bill read the first time and printed)